BCAXBicara Therapeutics Inc.
What is the market doing?
No clear lean: nothing decisive, though a crowded short (+18% of shares).
Rangebound, no clear trend. Oversold (RSI 23). Price is −15% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 9, 2026; selling is often routine (taxes, diversification).
A crowded short, settled Sep 30, 2026, more than a week of normal trading to cover, a crowded exit.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How BCAX is trading
Bicara Therapeutics Inc. is +68% over the past year while the S&P 500 is +18%: 49 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- −15%
vs 200-day average · a clear downtrend
- RSI (14)
- 23
RSI (14) · oversold, sold harder than it has been bought
- Below its 52-week high
- 39%
Below its 52-week high
Details›
- Last close2026-10-09
- $17.50
- 1 monthS&P 500 +2.7%
- −24%
- 1 yearS&P 500 +18%
- +68%
- vs 50-day average$22.72
- −23%
- 52-week high
- $28.86
- 52-week low
- $10.50
- Annualised volatility
- 74%
| Year | Return |
|---|---|
| 2026 (year to date) | +4.0% |
| 2025 | −3.4% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 2 | 0 of 2 | −14% |
| Feb | 2 | 1 of 2 | +2.6% |
| Mar | 2 | 1 of 2 | +8.3% |
| Apr | 2 | 2 of 2 | +9.4% |
| May | 2 | 1 of 2 | −17% |
| Jun | 2 | 2 of 2 | +11% |
| Jul | 2 | 2 of 2 | +11% |
| Aug | 2 | 1 of 2 | −3.2% |
| Sep | 2 | 1 of 2 | +6.3% |
| Oct | 3 | 1 of 3 | −3.3% |
| Nov | 2 | 1 of 2 | +1.0% |
| Dec | 2 | 0 of 2 | −13% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Biotechnology
The closest names by size in the same industry